LUYE PHARMA's stock surged 5.17% during intraday trading on Thursday, reflecting strong investor sentiment.
The sharp rise follows the company's release of its 2025 earnings report, which showed significant profit growth. Revenue increased by 4.1% year-on-year to RMB 6.308 billion, while profit attributable to shareholders jumped 31.12% to approximately RMB 619 million. The company attributed the revenue growth to higher sales and increased licensing income from certain products.